Vebreltinib Enteric-coated Capsules is a targeted therapy agent primarily indicated for the treatment of malignant tumors such as non-small cell lung cancer (NSCLC) with specific gene mutations. Its common adverse reactions include gastrointestinal disturbances (e.g., nausea, diarrhea), abnormal liver function and fatigue. In severe cases, it may trigger interstitial lung disease, cardiotoxicity or bleeding risk, which requires close clinical monitoring and prompt medical attention.
Common Adverse Reactions
Gastrointestinal reactions
Nausea, vomiting, diarrhea, anorexia and other symptoms, generally mild to moderate in severity, which may alleviate with prolonged medication.
Abnormal liver function
Elevated transaminases may occur in some patients, necessitating regular monitoring of liver function indices.
Cutaneous reactions
Rash, pruritus, xerosis and so on; a small number of patients may develop severe dermatitis.
Systemic symptoms
Asthenia, headache, edema (e.g., swelling of the extremities or face).
Severe Adverse Reactions (Immediate Medical Attention Required)
Interstitial lung disease/pneumonitis
Manifested as sudden dyspnea, aggravated cough or fever; immediate drug discontinuation and clinical intervention are mandatory.
Cardiac disorders
Including QT interval prolongation, cardiac arrhythmias or heart failure. Enhanced electrocardiographic monitoring is required for high-risk populations (e.g., patients with a history of heart disease).
Bleeding risk
Such as hemoptysis, melena, intracranial hemorrhage, etc., which is associated with the anti-angiogenic effect of the drug.
Severe infections
Pneumonia or other opportunistic infections may develop due to drug-induced immunosuppression.
Precautions
Comprehensive examinations shall be completed prior to medication initiation, including baseline assessments of liver function, electrocardiogram (ECG) and pulmonary function.
Regular follow-up and monitoring
Routine rechecks of blood routine, liver and renal function should be conducted every 2 to 4 weeks during treatment. Dosage adjustment or temporary drug suspension shall be implemented promptly if abnormalities are detected.
Drug-drug interactions
Concomitant use with potent CYP3A4 inhibitors (e.g., clarithromycin) or inducers (e.g., rifampicin) should be avoided, as such combinations may alter the plasma drug concentration.
Special populations
Dosage adjustment is required for patients with moderate to severe hepatic or renal insufficiency; the drug is contraindicated in pregnant and lactating women.
Medical Advice and Guidance for Seeking Medical Care
Vebreltinib is a prescription-only drug, and the dosage and treatment course prescribed by physicians must be strictly followed; self-discontinuation or arbitrary dosage adjustment is not permitted. In case of emergent symptoms such as persistent vomiting, jaundice, chest pain or confusion, emergency medical treatment should be sought immediately. It is recommended that patients record the onset time and severity of adverse reactions during treatment, so as to facilitate physicians' comprehensive assessment of the risk-benefit profile of the medication.
